Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

[1]  F. Saad,et al.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Stopeck,et al.  Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States , 2012, Journal of medical economics.

[3]  J. V. Von Roenn,et al.  American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Scagliotti,et al.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[6]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  I. Holen,et al.  Metastasis and bone loss: advancing treatment and prevention. , 2010, Cancer treatment reviews.

[8]  Xue Song,et al.  Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. , 2010, Journal of managed care pharmacy : JMCP.

[9]  Henrik Toft Sørensen,et al.  Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). , 2010, The Journal of urology.

[10]  G. Block,et al.  A Single-Dose Study of Denosumab in Patients With Various Degrees of Renal Impairment , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  I. Ray-Coquard,et al.  Drug management of prostate cancer: prevalence and consequences of renal insufficiency. , 2009, Clinical genitourinary cancer.

[12]  F. Saad,et al.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer. , 2009, The New England journal of medicine.

[13]  X. Mariette,et al.  Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Messa,et al.  Pathophysiology of Calcium and Phosphate Metabolism Impairment in Chronic Kidney Disease , 2009, Blood Purification.

[15]  R. Chlebowski,et al.  Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  David J Harrison,et al.  The cost of treating skeletal-related events in patients with prostate cancer. , 2008, The American journal of managed care.

[17]  X. Badia,et al.  Impact of skeletal complications on patients’ quality of life, mobility, and functional independence , 2008, Supportive Care in Cancer.

[18]  J. Abrahm,et al.  Spinal cord compression in patients with advanced metastatic cancer: "all I care about is walking and living my life". , 2008, JAMA.

[19]  P. Gascón,et al.  Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Oudard,et al.  Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management , 2007, Cancer.

[21]  M. Neary,et al.  The risk of renal impairment in hormone‐refractory prostate cancer patients with bone metastases treated with zoledronic acid , 2007, Cancer.

[22]  R. Coleman.  Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[23]  S. Cross,et al.  Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours , 2006, Journal of Clinical Pathology.

[24]  Miriam J. Johnson,et al.  Painful bone metastases: a prospective observational cohort study , 2005, Palliative medicine.

[25]  G. Oster,et al.  The Cost of Treatment of Skeletal-Related Events in Patients with Bone Metastases from Lung Cancer , 2005, Oncology.

[26]  M. Krzakowski,et al.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Logothetis,et al.  Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  L. Hofbauer,et al.  Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[30]  A. Howell,et al.  Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. , 2001, Cancer journal.

[31]  R. Coleman,et al.  The management of bone metastases. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  G. Hortobagyi,et al.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  G. Hortobagyi,et al.  Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[35]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[36]  P. Kostenuik,et al.  Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis , 2007, Clinical & Experimental Metastasis.